Literature DB >> 21646371

Nephrolithiasis and renal calcifications in primary hyperparathyroidism.

Lars Rejnmark1, Peter Vestergaard, Leif Mosekilde.   

Abstract

CONTEXT: Renal complications in terms of hypercalciuria, nephrolithiasis, and nephrocalcinosis are well-known risks in primary hyperparathyroidism (PHPT) and may lead to impaired renal function. EVIDENCE ACQUISITION: We reviewed published evidence on the occurrence, pathophysiology, and consequences of renal complications in PHPT and highlighted areas of uncertainty that should be investigated further. EVIDENCE SYNTHESIS: In asymptomatic PHPT, renal stones are present in approximately 7% of the patients, which is a significantly higher prevalence than among patients without PHPT (1.6%). Also, before diagnosis of PHPT, risk of hospital admissions due to renal stones is increased compared with the background population, and the risk remains increased for at least 10 yr after surgical cure from PHPT. However, shortly after parathyroidectomy, risk of recurrent stone episodes is reduced to the recurrence rate among patients with idiopathic renal stone disease. In general, patients with PHPT who develop nephrolithiasis are of younger age and more often are males, compared with those who do not form renal calcifications. Although 24-h urinary calcium is decreased after parathyroidectomy, studies have shown a higher renal calcium excretion and lower serum phosphate levels in former PHPT patients compared with healthy controls, suggesting that these patients have some additional mineral disorder.
CONCLUSION: All patients with a diagnosis of PHPT should initially be evaluated for renal calcifications by unenhanced helical computed tomography. If calcifications are present, parathyroidectomy is recommended. If symptoms develop after parathyroidectomy, patients should be evaluated and treated similar to other patients with renal stones.

Entities:  

Mesh:

Year:  2011        PMID: 21646371     DOI: 10.1210/jc.2011-0569

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

1.  Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?

Authors:  F Saponaro; F Cetani; L Mazoni; M Apicella; M Di Giulio; F Carlucci; M Scalese; E Pardi; S Borsari; J P Bilezikian; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-12-23       Impact factor: 4.256

2.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Authors:  C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola
Journal:  J Endocrinol Invest       Date:  2015-03-28       Impact factor: 4.256

3.  Subclinical urolithiasis in patients with asymptomatic primary hyperparathyroidism.

Authors:  Hussam Abusahmin; John Geen; Gautam Das
Journal:  Ther Adv Endocrinol Metab       Date:  2018-07-24       Impact factor: 3.565

4.  24-hour urinary calcium in primary hyperparathyroidism.

Authors:  Carrie E Black; Richard L Berg; Andrew C Urquhart
Journal:  Clin Med Res       Date:  2013-12

Review 5.  [Asymptomatic primary hyperparathyroidism : Operation or observation?]

Authors:  Katja Gollisch; Heide Siggelkow
Journal:  Internist (Berl)       Date:  2021-03-12       Impact factor: 0.743

6.  Polymorphisms of CASR gene increase the risk of primary hyperparathyroidism.

Authors:  X-M Wang; Y-W Wu; Z-J Li; X-H Zhao; S-M Lv; X-H Wang
Journal:  J Endocrinol Invest       Date:  2015-12-28       Impact factor: 4.256

7.  Metabolic disorders: stones as first clinical manifestation of significant diseases.

Authors:  Jean-Philippe Haymann
Journal:  World J Urol       Date:  2014-09-05       Impact factor: 4.226

8.  Predictors of renal function in primary hyperparathyroidism.

Authors:  Marcella D Walker; Thomas Nickolas; Anna Kepley; James A Lee; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

9.  Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Authors:  Emanuela Traini; Rocco Bellantone; Serena Elisa Tempera; Salvatore Russo; Carmela De Crea; Celestino Pio Lombardi; Marco Raffaelli
Journal:  Langenbecks Arch Surg       Date:  2018-03-14       Impact factor: 3.445

10.  Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms.

Authors:  A Trombetti; E R Christ; C Henzen; G Gold; M Brändle; F R Herrmann; C Torriani; F Triponez; M Kraenzlin; R Rizzoli; C Meier
Journal:  J Endocrinol Invest       Date:  2016-01-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.